Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19

Hypertens Res. 2020 Aug;43(8):837-840. doi: 10.1038/s41440-020-0478-1. Epub 2020 May 20.

Authors

Masato Furuhashi¹, Norihito Moniwa², Hideki Takizawa³, Nobuyuki Ura⁴, Kazuaki Shimamoto⁵

Affiliations

¹ Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan. furuhasi@sapmed.ac.jp.
² Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
³ Department of Nephrology, Teine Keijinkai Hospital, Sapporo, Japan.
⁴ Sapporo Nishimaruyama Hospital, Sapporo, Japan.
⁵ Japan Health Care College, Sapporo, Japan.

No abstract available

Publication types

Editorial

MeSH terms

Angiotensin Receptor Antagonists / pharmacology*
Angiotensin Receptor Antagonists / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Animals
Betacoronavirus
COVID-19
Coronavirus Infections / complications*
Coronavirus Infections / mortality
Humans
Hypertension / complications
Hypertension / drug therapy
Lung Injury / virology*
Pandemics
Pneumonia, Viral / complications*
Pneumonia, Viral / mortality
Renin-Angiotensin System / drug effects*
SARS-CoV-2

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors